New pharmacological approaches to a functional cure of hepatitis B
Authors:
- 27 October 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 8 (4) , 83-88
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa studyJournal of Hepatology, 2016
- NVR 3-778, a First-in-Class HBV Core Inhibitor, Alone and in Combination with Peg-Interferon (PegIFN), in Treatment-Naive HBeAg-Positive Patients: Early Reductions in HBV DNA and HBeAgJournal of Hepatology, 2016
- Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520Journal of Hepatology, 2016
- Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intentAntiviral Research, 2015
- Present and future therapies of hepatitis B: From discovery to cureHepatology, 2015
- CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virusScientific Reports, 2015
- O114 : Serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-CAJournal of Hepatology, 2015
- Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective studyGut, 2014
- An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector NucleasesMolecular Therapy, 2014
- HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular CarcinomaGastroenterology, 2008